我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 PFIZER INC.
相关临床试验
147
124 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1977
进行中（未招募）
123
83.7%
已完成
10
6.8%
尚未招募
1
0.7%
招募中
13
8.8%
暂无批准数据
• The Crohn's disease market is experiencing growth, driven by increasing prevalence and advances in treatment options, with the market size expected to increase from USD ~9,000 million in 2023. • Emerging therapies like mirikizumab, guselkumab and biosimilars of ustekinumab are showing promise in clinical trials, offering improved efficacy and targeted mechanisms of action for Crohn's disease management. • Pharmaceutical companies such as Eli Lilly, Janssen, Takeda, and Dong-A-ST are actively involved in developing and launching novel treatments, including biologics and biosimilars, to address unmet needs in Crohn's disease. • Clinical trials are focusing on histologic outcomes and endoscopic remission, indicating a shift towards more comprehensive assessments of treatment efficacy in Crohn's disease patients.
